Mylan Inc. (MYL)

Check out top investors' recommendation for MYL
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
45.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Andrew Finkelstein Susquehanna Financial Group Buy   Nov 07, '17     47.00  Nov 07, '18  N/A 
Gary Nachman Susquehanna Financial Group Buy   Oct 30, '17     45.00  Oct 30, '18  N/A 
Marc Goodman UBS Buy   Oct 05, '17     46.00  Oct 05, '18  N/A 
Tim Chiang CRT Capital Group Buy   Oct 04, '17     45.00  Oct 04, '18  N/A 
Liav Abraham Citi Buy   Oct 04, '17     42.00  Oct 04, '18  N/A 
Gary Nachman Susquehanna Financial Group Buy   Sep 29, '17     45.00  Sep 29, '18  N/A 
Liav Abraham Citi Buy   Aug 16, '17     42.00  Aug 16, '18  N/A 
Gary Nachman Susquehanna Financial Group Buy   Jul 13, '17     50.00  Jul 13, '18  N/A 
Douglas Tsao Barclays Buy   May 22, '17     50.00  May 22, '18  N/A 
Jason Gerberry Leerink Swann Llc Buy   Mar 06, '17       Mar 06, '18  N/A 
Gerardo Torculas Unaffiliated Buy   Aug 26, '16   43.03  46.00  Sep 26, '16  -2.25% 
Gregg Gilbert BofA Merrill Lynch Buy   Aug 24, '16     70.00  Aug 24, '17  N/A 
Jason Gerberry Leerink Swann Llc Buy   Aug 15, '16     55.00  Aug 15, '17  N/A 
Jami Rubin Goldman Sachs Buy   May 13, '16   39.16    May 13, '17  -0.56% 
Jason Gerberry Leerink Swann Llc Buy   May 04, '16     51.00  May 04, '17  N/A 
Jason Gerberry Leerink Swann Llc Buy   Feb 16, '16   43.15  50.00  Feb 16, '17  -1.65% 
Liav Abraham Citi Buy   Feb 11, '16   41.42  59.00  Feb 11, '17  -5.09% 
Chris Schott JPMorgan Buy   Feb 11, '16   41.42  62.00  Feb 11, '17  -5.09% 
Jami Rubin Goldman Sachs Buy   Dec 17, '15   52.97    Dec 17, '16  N/A 
Liav Abraham Citi Buy   Nov 13, '15   48.78    Nov 13, '16  N/A 
< previous123